Phase 3 LEAP-012 Trial Offers A New Option for Intermediate-Stage HCC Management
September 17th 2024The trial demonstrated that the combination of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival and objective response rates compared to TACE alone.
Read More
The DETECT V Trial: Exploring Chemotherapy-Free Treatment for HER2+/HR+ Metastatic Breast Cancer
September 16th 2024Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.
Read More
Rising Incidence of Young-Onset Cancer: Exploring the Causes and Generational Risk Factors
September 16th 2024At ESMO Congress 2024, Shuji Ogino, MD, PhD, MS, explained that the rising incidence of young-onset cancer may be due to generational risk factors such as lifestyle, diet, and environmental changes, emphasizing the need for long-term research and follow up to understand early-life influences on cancer development.
Read More
Managing Treatment With New and Expensive Drugs: What Pharmacy Leaders Need to Know
September 16th 2024With the introduction of expensive drugs and associated challenges for hospital budgets, pharmacy leaders benefit from strategically managing financial, clinical, and regulatory factors for sustainable care delivery.
Read More